Dr Gene Dempsey, Consultant Neonatologist, Cork University Maternity Hospital and Department of Paediatrics and Child Health UCC, is Project Coordinator for the Trial funded under the EU FP7 framework. The HIP team is made up of 13 partners with the intention of enrolling 750 ELGAN over the next 3 years and will follow these infants over the first two years of life to assess their long-term development.

The HIP consortium includes 13 research groups operating in seven different countries across Europe and North America, including 3 SMEs, whose specific complementary expertise will highly contribute to the HIP specific innovation oriented work packages. The consortium brings together experts in the field of neonatology, clinical trials, scientists, neurophysiologists, pharmacologists and business; all with one achievable goal: to ensure that the most vulnerable newborn infants receive the most appropriate treatment and to ensure that these treatments come to the market and their use is widely made available.

“We are fortunate to have leaders in neonatal cardiovascular support, neonatal echocardiography, neonatal near infrared spectroscopy, neonatal EEG monitoring, neonatal pharmacology, neonatal clinical trialists and neonatal follow-up. The technical and scientific competence along with the proven capability for international cooperation across the groups will result in the realisation of the objectives of HIP and will have worldwide implications for the care of the ELGAN”, explained Dr Dempsey.

<<Previous Item

« Back to 2010 Press Releases